Novartis' MS drug Gilenya could inspire new chronic kidney disease treatment

Novartis’ multiple sclerosis therapy Gilenya was once proposed as a kidney disease treatment because its ability to modulate S1P receptors could theoretically tamp down inflammation. Although that idea didn’t pass the clinical test, the search for better kidney disease drugs targeting the same pathway remains ongoing.